Plasma HBV DNA < 60 UI/mL | Plasma HBV DNA > 60 UI/mL | OR | 95% CI | p | |
---|---|---|---|---|---|
Sex | 0. 79 | ||||
female | 2 (66. 67%) | 1(33. 33%) | 1. 00 | ||
male | 48(59. 26%) | 33(40. 74%) | 1. 37 | 0. 11-15. 79 | |
Age | 0. 41 | ||||
< = 42 | 22(55%) | 18(45%) | 1. 00 | ||
> 42 | 27(62. 79%) | 16(37. 21%) | 0. 72 | 0. 30-1. 74 | |
CD4 | 0. 47 | ||||
< 350 cels/μ1 | 14 (53. 85%) | 12(46. 15%) | 1. 00 | ||
> 350 cels/μ1 | 36 (62. 07%) | 22 (37. 93%) | 0. 71 | 0. 27-1. 81 | |
Under HAART* | 0. 005 | ||||
yes | 50(63. 29%) | 29(36. 71%) | |||
no | zero | 05 (100%) | |||
HBV Genotype | |||||
A | 4 (20%) | 16 (80%) | 0. 36 | 0-2. 9 | 0. 63 |
Non-A | 1 (8. 3%) | 11 (91. 6%) | 1. 00 | ||
Previous exposure to LAM | 0. 10 | ||||
no | 2(28. 57%) | 5(71. 43%) | 1. 00 | ||
yes | 48(62. 34%) | 29(37. 66%) | 0. 24 | 0. 04-1. 32 | |
Under TDF | 0. 005 | ||||
no | 15(17. 8%) | 21(25. 16%) | 1. 00 | ||
yes | 35(41. 6%) | 13(15. 4%) | 0. 26 | 0. 10-0. 66 | |
Use of TDF > 12 months | 0. 047 | ||||
no | 21(25%) | 27(32. 1%) | 1. 00 | ||
yes | 29(34. 5%) | 7(8. 2%) | 0. 24 | 0. 059-0. 97 | |
ALT level | 0. 004 | ||||
Normal | 44(53. 6%) | 19(23. 1%) | 1. 00 | ||
> 1. 5 ULN** | 6(7. 3%) | 13(15. 7%) | 5. 01 | 1. 65-15. 17 | |
Compliance with therapy | 0. 033 | ||||
no | 01(14. 29%) | 06(85. 71%) | 10. 5 | 1. 20-91. 71 | |
yes | 49(63. 64%) | 28(36. 36%) | 1. 00 |